CANDEL THERAPEUTICS INC(NASDAQ:CADL) stock News

CADL Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Benzinga - Mentions: VDC XLP TRIN ABT ...

EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards

9 days ago - By: Candel Therapeutics

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

9 days ago - By: Candel Therapeutics

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

10 days ago - By: Benzinga - Mentions: BCRX XNCR SNTI ADAP ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

11 days ago - By: Stocktwits - Mentions: VTWG URTY

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer

2 months ago - By: The Motley Fool

Candel Reports 88 Percent Q2 Loss Drop

11 days ago - By: Trinity Capital Inc. - Mentions: TRIN

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

11 days ago - By: Candel Therapeutics

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

11 days ago - By: Candel Therapeutics - Mentions: TRIN

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

11 days ago - By: Candel Therapeutics

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

11 days ago - By: Candel Therapeutics

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

22 days ago - By: Candel Therapeutics

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

22 days ago - By: Candel Therapeutics

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

26 days ago - By: Candel Therapeutics

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

26 days ago - By: Candel Therapeutics

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

a month ago - By: Candel Therapeutics

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

a month ago - By: Candel Therapeutics

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

2 months ago - By: Candel Therapeutics

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

2 months ago - By: Candel Therapeutics

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

2 months ago - By: Candel Therapeutics

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

2 months ago - By: Candel Therapeutics

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

2 months ago - By: Candel Therapeutics

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

2 months ago - By: Candel Therapeutics

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

3 months ago - By: Candel Therapeutics

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

3 months ago - By: Candel Therapeutics